Dr. Christina Baik is an Associate Professor for the University of Washington and a medical oncologist for the Thoracic Head and Neck Oncology group at the Seattle Cancer Care Alliance. She received her MD from the University of Rochester School of Medicine in Rochester, New York and her Masters in Public Health from Harvard School of Public Health, Boston, Massachusetts. She completed her Hematology-Oncology clinical fellowship at Tufts Medical Center, Boston, MA and completed her post-doctorate fellowship here at the Fred Hutchinson Cancer Research Center, Seattle, WA. Her clinical and research interest is in thoracic malignancies, especially in the development of novel targeted therapeutics in patients with driver genetic alterations.
The field of targeted therapeutic development in non-small cell lung cancer (NSCLC) is rapidly advancing. As of late 2020, there are seven actionable oncogenic alterations in NSCLC: EGFR mutation (non-exon 20 insertion), ALK fusion, ROS1 fusion, BRAF V600E mutation, NTRK fusion, MET exon 14 skip mutation and RET fusion. There is also active investigation into oncogenic alterations which were previously thought to be undruggable such as KRAS and exon 20 insertion mutations. In this presentation, I will discuss the data for new targeted therapies in NSCLC (RET, MET, NTRK, KRAS, exon 20 insertion). This advance underscores the importance of comprehensive molecular testing in patients with NSCLC so that scientific discoveries and breakthroughs lead to improved outcomes in this patient population.